Speciality Medicines Secures Ethiopian Approval for Two Formulations
Speciality Medicines Ltd 路 Others (Uncategorized) 路 12 Aug 2026, 10:37 pm
Speciality Medicines Secures Ethiopian Approval for Two Formulations Speciality Medicines (SPML) announced on 12 Aug'26 that it received regulatory approval from Ethiopian health authorities for two new products: Olanzapine 5 mg (Olazyn 5) and Diazepam 5 mg (Diazem 5). This approval expands the company's registered product portfolio in Ethiopia to 12 formulations, strengthening its presence in a key export market. The company continues to advance its international portfolio, which also includes two registered products in Peru, reinforcing its export-focused strategy across semi-regulated global markets.
Original exchange filing (PDF)
More announcements from Speciality Medicines Ltd
- We hereby submit the Standalone Unaudited Financial Result for the half year ended on September 30, 2026 路 12 Nov 2026
- We hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on November 12, 2026, at the Corporate Office of the Company which was commenced .... 路 12 Nov 2026
- Speciality Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve 1. Unaudited Standalone .... 路 12 Nov 2026
- We hereby submit Voting Results and Consolidated Scrutinizer report of the 5th AGM of the Company. 路 28 Sept 2026
- We hereby submit Proceedings of 5th AGM of the Company. 路 28 Sept 2026
- We hereby Submit Annual Report of FY 2025-26. 路 04 Sept 2026
- We hereby submit Notice of 5th AGM to be held on September 28, 2026. 路 04 Sept 2026
- We hereby submit Outcome of the board meeting held on September 03, 2026 路 03 Sept 2026
